18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors
作者： Rodney J. Hicks , Amir Iravani , Shahneen Sandhu
DOI: 10.1016/J.CPET.2019.08.007
关键词:
摘要: The complexity of the immune response and diversity targets challenges conventional conceptual frameworks used in selecting monitoring treatment with check-point inhibitors. limitations anatomic imaging assessing have been recognized. Varying patterns These different implications for continuation duration therapy. Evidence supporting role 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography as a prognostic biomarker characterizing is presented. An added benefit this approach ability to detect immune-related inflammatory reactions, often advance severe or life-threatening clinical manifestations.
elsevier.com
sci-hub.se 参考文章(61)
Terue Okamura, Tadashi Takeda, Shinya Nakajima, Tadashi Yokogawa, Tetsuo Kuroki, Shuhei Nishiguchi, Hironobu Ochi, Susumu Shiomi, Takashi Tanaka, Changes in results of Gallium-67-citrate scanning after interferon therapy for chronic hepatitis C. The Journal of Nuclear Medicine. ,vol. 38, pp. 216- 219 ,(1997)
Daniel S. Chen, Ira Mellman, Oncology Meets Immunology: The Cancer-Immunity Cycle Immunity. ,vol. 39, pp. 1- 10 ,(2013) , 10.1016/J.IMMUNI.2013.07.012
Christos Sachpekidis, Lionel Larribere, Leyun Pan, Uwe Haberkorn, Antonia Dimitrakopoulou-Strauss, Jessica C. Hassel, Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 42, pp. 386- 396 ,(2015) , 10.1007/S00259-014-2944-Y
Bernhard Mlecnik, Gabriela Bindea, Franck Pagès, Jérôme Galon, Tumor immunosurveillance in human cancers Cancer and Metastasis Reviews. ,vol. 30, pp. 5- 12 ,(2011) , 10.1007/S10555-011-9270-7
J. D. Wolchok, A. Hoos, S. O'Day, J. S. Weber, O. Hamid, C. Lebbe, M. Maio, M. Binder, O. Bohnsack, G. Nichol, R. Humphrey, F. S. Hodi, Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria Clinical Cancer Research. ,vol. 15, pp. 7412- 7420 ,(2009) , 10.1158/1078-0432.CCR-09-1624
Zachary A. Cooper, Dennie T. Frederick, Zain Ahmed, Jennifer A. Wargo, Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma. OncoImmunology. ,vol. 2, ,(2013) , 10.4161/ONCI.24320
T. Okazaki, T. Honjo, PD-1 and PD-1 ligands: from discovery to clinical application. International Immunology. ,vol. 19, pp. 813- 824 ,(2007) , 10.1093/INTIMM/DXM057
Annick D Van den Abbeele, Ramsey D Badawi, None, Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). European Journal of Cancer. ,vol. 38, ,(2002) , 10.1016/S0959-8049(02)80604-9
Margaret K. Callahan, Jedd D. Wolchok, James P. Allison, Anti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy Seminars in Oncology. ,vol. 37, pp. 473- 484 ,(2010) , 10.1053/J.SEMINONCOL.2010.09.001
R. L. Wahl, H. Jacene, Y. Kasamon, M. A. Lodge, From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors The Journal of Nuclear Medicine. ,vol. 50, ,(2009) , 10.2967/JNUMED.108.057307